Dyax Presents DX-4012 Data At The 2015 American Society of Hematology Annual Meeting

BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced a poster presentation describing preclinical data for DX-4012, the Company’s fully human monoclonal antibody to activated Factor XII (Factor XIIa), was presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 5-8, 2015 in Orlando, Florida.

“The poster presented at ASH this year describes how DX-4012 demonstrated anti-thrombotic activity in various animal models, without evidence of increased bleeding risk”

“The poster presented at ASH this year describes how DX-4012 demonstrated anti-thrombotic activity in various animal models, without evidence of increased bleeding risk,” said Burt Adelman M.D., Chief Medical Officer and Executive Vice President of Research and Development at Dyax. “These data are a significant achievement for the Dyax research team and indicate that DX-4012, either as a monoclonal antibody or as a component of a bispecific antibody, shows potential as a novel antithrombotic therapy.”

A summary of data presented is below:

Title: Discovery and Characterization of a Highly Specific Antibody Inhibitor of Factor XIIa (FXIIa), and the Subsequent Generation of Factor XIIa/Plasma Kallikrein (PK) Bispecific Antibody
Date and time: Sunday, December 6, 2015 from 6:00 – 8:00pm ET
Abstract #: 83101
Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster II
Location: Hall A, Level 2
Summary: In this report, investigators describe the discovery and preclinical evaluation of DX-4012 as a highly selective and potent inhibitor of FXIIa. DX-4012 inhibits the proteolytic activity of FXIIa with an apparent Ki of ~15 pM, and does not inhibit closely related sequence homologs or other coagulation factors at concentrations up to 1 µM. When tested at 1 µM in human plasma, DX-4012 prolonged the activated partial thromboplastin time (aPTT) 3.4-fold, with no effect on the prothrombin time (PT). In a baboon arteriovenous shunt model of thrombosis, a single 10mg/kg intravenous infusion reduced platelet and fibrin deposition up to 192 hours after administration, demonstrating an antithrombotic effect with no increased risk of bleeding.

About DX-4012
Discovered using Dyax’s proprietary phage display technology platform, DX-4012 is a fully human monoclonal antibody inhibitor of FXIIa. Preclinical data indicate that DX-4012 shows potential as a novel antithrombotic therapy. Current areas of interest for this investigational product candidate are extracorporeal membrane oxygenation (ECMO), lupus anticoagulant syndrome and as a potential alternative treatment for patients who require prolonged antithrombotic therapy but cannot tolerate conventional anticoagulation.

About Dyax
Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.

Both DX-2930 and KALBITOR were identified using Dyax's proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes two FDA approved products and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and royalties.

For additional information about Dyax, please visit www.dyax.com.

For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.

Disclaimer
The press release contains forward-looking statements, including statements regarding the prospects for an investigational product, DX-4012. Statements that are not historical facts are based on Dyax’s current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this press release are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. There are many factors that could cause actual results to differ materially from those in these forward-looking statements. These factors include the following: the results from pre-clinical studies may not be predictive of the results or success of future clinical trials that will be required to permit application for regulatory approval of DX-4012; even if DX-4012 progresses through clinical trials and gains regulatory approval, it may not gain market acceptance; others may develop technologies or products superior to DX-4012; Dyax is dependent on the expertise, effort, priorities and contractual obligations of third parties in the manufacture, quality control, storage and clinical development of DX-4012; the costs of prosecuting, maintaining, defending and enforcing our patents and other intellectual property rights; the overall condition of the financial markets; and a variety of other risks common to our industry; changing requirements and costs associated with Dyax's planned research and development activities; the uncertainty of patent and intellectual property protection; and other risk factors described or referred to in Item 1A, “Risk Factors” in Dyax’s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.

Dyax, the Dyax logo and KALBITOR are registered trademarks of Dyax Corp.

Dyax
Jennifer Robinson, 617-250-5741
Director, Investor Relations and Corporate Communications
jrobinson@dyax.com

Back to news